Task: gap021 | Last Updated: 2026-03-15 | Kind: gap-analysis | Total Gaps Identified: 9
Knowledge Gap: What is the role of microglia in FTD progression?
This page explores the critical but incompletely understood contribution of microglia to frontotemporal dementia (FTD) pathogenesis, covering microglial activation patterns, key receptor pathways, and therapeutic implications.
Frontotemporal dementia (FTD) encompasses a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and temporal lobes. While neuron-centric views have historically dominated FTD research, emerging evidence positions microglia as key drivers of disease progression[1]. Microglia, the resident immune cells of the brain, participate in synaptic pruning, debris clearance, and neuroinflammation—all processes implicated in FTD pathogenesis[2].
The recognition that FTD-linked genetic mutations (GRN, C9orf72, MAPT) directly affect microglial function has catalyzed interest in understanding how these cells contribute to disease progression and whether they represent viable therapeutic targets.
Microglia arise from embryonic yolk sac progenitors and colonize the brain during early development, maintaining self-renewal throughout life[3]. In the healthy brain, microglia exist in a surveillance state characterized by:
| Function | Description | Relevance to FTD |
|---|---|---|
| Synaptic pruning | Elimination of excess synapses during development and plasticity | Dysregulated in FTD; contributes to connectivity loss |
| Debris clearance | Phagocytosis of dead cells and protein aggregates | May be overwhelmed in FTD |
| Immune surveillance | Detection of pathogens and damage signals | Chronic activation in FTD |
| trophic support | Secretion of neurotrophic factors | Potential therapeutic target |
Microglia in FTD exhibit diverse activation states that differ from classical M1/M2 paradigms. Single-cell studies have identified disease-specific microglial phenotypes[1:1]:
DAM, also termed microglia in a disease context, represent a spectrum of activation states:
Transcriptomic analyses of FTD brain tissue reveal distinct microglial signatures:
Quantitative studies demonstrate:
Triggering receptor expressed on myeloid cells 2 (TREM2) is a critical microglial surface receptor implicated in FTD risk[4]:
| Variant | Effect | FTD Association |
|---|---|---|
| R47H | Reduced ligand binding | Increased AD risk |
| R62H | Partial loss of function | Moderate risk |
| D87N | Altered glycosylation | Variable |
| Loss-of-function | Complete deficiency | Rare; severe phenotype |
While TREM2 variants are most strongly associated with Alzheimer's disease, they modify FTD progression and may influence age of onset in GRN carriers[5].
TREM2 activation triggers multiple intracellular pathways:
Progranulin (GRN) is highly expressed in microglia, where it serves multiple functions[2:1]:
Heterozygous GRN mutations cause FTD through haploinsufficiency, with microglial dysfunction as a key contributor:
The progranulin-microglia-neuron axis represents a critical pathway in FTD:
Neurons ←→ Microglia ←→ Astrocytes
↓ ↓ ↓
TDP-43 Progranulin Neuroinflammation
pathology deficiency amplification
Key interactions include:
Elevated levels of multiple cytokines and chemokines have been documented in FTD:
| Mediator | Source | Effect | Evidence Level |
|---|---|---|---|
| IL-1β | Microglia, astrocytes | Pro-inflammatory | Moderate |
| IL-6 | Microglia, neurons | Acute phase response | High |
| TNF-α | Microglia | Cytotoxicity | Moderate |
| CXCL8 | Microglia | Chemotaxis | Moderate |
| CCL2 | Various | Monocyte recruitment | High |
Evidence for BBB compromise in FTD includes:
Peripheral immune alterations in FTD:
| Strategy | Target | Stage | Challenges |
|---|---|---|---|
| TREM2 agonism | TREM2 | Preclinical | Agonist development, BBB penetration |
| Anti-inflammatory | IL-1β, TNF-α | Preclinical | Broad immunosuppression risk |
| Progranulin augmentation | GRN expression | Preclinical | Delivery to CNS |
| Complement inhibition | C1q, C3 | Preclinical | Synaptic function maintenance |
Gene therapy approaches aim to restore progranulin levels:
Rational combinations under investigation:
| Trial | Phase | Focus | Status |
|---|---|---|---|
| NCT05566647 | Observational | GRN carrier biomarker study | Recruiting |
| NCT06328974 | Preclinical | TREM2 modulator efficacy | Preclinical |
Kim et al. Microglial activation in FTD subtypes (2022). 2022. ↩︎ ↩︎
Lowe et al. Microglia in FTD progression (2018). 2018. ↩︎ ↩︎
Ferrari et al. Neuroinflammation in FTD (2019). 2019. ↩︎
Hansen et al. TREM2 and microglia function (2021). 2021. ↩︎
Simon et al. TREM2 microglia targeting in neurodegenerative disease (2024). 2024. ↩︎
Gordon et al. AAV9-GRN delivery in preclinical FTD models. 2024. ↩︎
Singhi et al. Microglial subpopulations in FTD by snRNA-seq. 2024. ↩︎
Yang et al. TREM2 deficiency accelerates GRN-deficient pathology. 2024. ↩︎
Balmforth et al. TREM2 agonistic antibodies in FTD models. 2024. ↩︎
Swanton et al. CSF microglial markers correlate with FTD progression. 2024. ↩︎
Orr et al. Spatial transcriptomics of FTD microglial activation. 2024. ↩︎